 PRINCETON, N.J., Aug. 05, 2021 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. Nasdaq: OYST, Oyster Point Pharma or the Company a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced its financial results for the second quarter of 2021, and provided an overview of recent business highlights. 